MCID: GST012
MIFTS: 36

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 14
Adenocarcinoma of the Gastroesophageal Junction 69
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4944
NCIt 46 C9296
UMLS 69 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and esophagitis, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are MAPK Pathway and Adherens junction. The drugs Herceptin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate.

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.8
2 esophagitis 10.2
3 blood group, i system 10.1
4 helicobacter pylori infection 10.0
5 sclerosing cholangitis, neonatal 9.8
6 meningitis 9.8
7 gastrointestinal system cancer 9.7 ERBB2 SNAI1
8 keratoconjunctivitis sicca 9.6 ERBB2 IL1B
9 cercarial dermatitis 9.6 IL1B SNAI1
10 colorectal cancer 8.6 ERBB2 GUCY2C IL1B SNAI1

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Herceptin 17 45 TRASTUZUMAB Genentech October 1998

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
4
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3, Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
8
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
9
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
10
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
11
Cetuximab Approved Phase 3,Phase 2 205923-56-4 56842117 2333
12
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
13
Epirubicin Approved Phase 3,Phase 2,Early Phase 1 56420-45-2 41867
14
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
15
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
16
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
19
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3, Phase 1 114977-28-5 148124 9877265
20
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3, Phase 1 231277-92-2, 388082-78-8 208908 9941095
21 Antimitotic Agents Phase 2, Phase 3, Phase 1
22 Antibodies Phase 3,Phase 2,Phase 1
23 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
24 Immunoglobulins Phase 3,Phase 2,Phase 1
25 Mitogens Phase 3,Phase 2,Phase 1
26 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29
s 1 (combination) Phase 3,Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 2, Phase 3
31 Angiogenesis Modulating Agents Phase 2, Phase 3
32 Analgesics Phase 3,Phase 1
33 Antiemetics Phase 3
34 Appetite Stimulants Phase 3
35 Central Nervous System Stimulants Phase 3
36 Endothelial Growth Factors Phase 3,Phase 1
37 Opiate Alkaloids Phase 3
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
39 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
41 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
42 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
45 Alkylating Agents Phase 3
46 Mitomycins Phase 3
47 Nucleic Acid Synthesis Inhibitors Phase 3
48 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
49 Ado-trastuzumab emtansine Phase 2, Phase 3,Phase 1
50 Maytansine Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 159)

# Name Status NCT ID Phase Drugs
1 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Unknown status NCT01786278 Phase 2, Phase 3
2 A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Unknown status NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
3 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
4 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
5 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
6 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
7 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed NCT01170663 Phase 3 Placebo;Paclitaxel
8 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
9 Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE- Recruiting NCT03019588 Phase 3 Paclitaxel
10 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
11 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
12 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
13 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
14 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
15 Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Recruiting NCT02381847 Phase 3
16 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3 capecitabine
17 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Recruiting NCT02158988 Phase 3
18 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
19 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
20 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Recruiting NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
21 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Active, not recruiting NCT02370498 Phase 3 paclitaxel
22 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Active, not recruiting NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
23 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
24 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
25 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting NCT02494583 Phase 3 cisplatin;5-FU;capecitabine
26 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Active, not recruiting NCT02178956 Phase 3 BBI608;Paclitaxel
27 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
28 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
29 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
30 A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine
31 A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer Terminated NCT01450696 Phase 3 Capecitabine;Cisplatin;Herceptin
32 First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma Terminated NCT01697072 Phase 3 Rilotumumab;Epirubicin;Cisplatin;Capecitabine
33 A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Terminated NCT01641939 Phase 2, Phase 3 Taxane;trastuzumab emtansine;trastuzumab emtansine
34 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
35 Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
36 Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer Unknown status NCT02525237 Phase 2 Apatinib;S-1
37 Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Unknown status NCT01359397 Phase 2 Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab;Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
38 Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer Unknown status NCT00865982 Phase 2 Docetaxel, Cisplatin, Capecitabine
39 Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Unknown status NCT01855854 Phase 2 Icotinib
40 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
41 Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer Unknown status NCT01307956 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
42 Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00813072 Phase 2 PEP02;irinotecan;docetaxel
43 Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2 irinotecan hydrochloride;cisplatin
44 Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00183872 Phase 2 irinotecan, docetaxel
45 Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach Completed NCT01472029 Phase 2 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab;Post-operative treatment trastuzumab mono therapy
46 Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment Completed NCT01262482 Phase 2 Oxaliplatin;Sorafenib
47 Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Completed NCT00074009 Phase 2 bortezomib
48 Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma Completed NCT01932580 Phase 2 FLOT (5-fluorouracil, oxaliplatin, docetaxel)
49 Docetaxel+Oxali+/-Cetux Met Gastric/GEJ Completed NCT00517829 Phase 2 Docetaxel;cetuximab;oxaliplatin
50 Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer Completed NCT00737373 Phase 2 Docetaxel;5-Fluorouracil;Oxaliplatin;folinic acid

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

38
Breast, Testes, Prostate, Endothelial, Lung, Bone, Lymph Node

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 73)
# Title Authors Year
1
Unusual case of left atrial myxoma with gastroesophageal junction adenocarcinoma. ( 29338297 )
2018
2
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. ( 29094609 )
2018
3
Perioperative chemotherapy vs. neoadjuvant chemoradiation inA gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. ( 29071366 )
2018
4
Testicular Metastasis from Recurrent Gastroesophageal Junction Adenocarcinoma: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings. ( 29430123 )
2018
5
Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. ( 29277796 )
2018
6
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. ( 28852939 )
2017
7
External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. ( 28951752 )
2017
8
Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. ( 29199662 )
2017
9
HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )
2017
10
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. ( 28424936 )
2017
11
Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. ( 28524708 )
2017
12
Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. ( 28500616 )
2017
13
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. ( 28574779 )
2017
14
Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. ( 28491144 )
2017
15
Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )
2016
16
Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )
2016
17
No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )
2016
18
Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )
2016
19
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )
2016
20
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )
2016
21
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )
2015
22
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )
2015
23
Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )
2015
24
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )
2015
25
Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )
2014
26
Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )
2014
27
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )
2014
28
Reconstructive options for gastroesophageal junction adenocarcinoma after Roux-en-Y gastric bypass. ( 23988286 )
2013
29
The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. ( 23671646 )
2013
30
Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. ( 24949383 )
2013
31
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. ( 23656792 )
2013
32
The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. ( 23420289 )
2013
33
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. ( 24236193 )
2013
34
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( 23921575 )
2013
35
Meningeal carcinomatosis: a metastasis from gastroesophageal junction adenocarcinoma. ( 24454393 )
2013
36
Unanswered questions in the management of gastroesophageal junction adenocarcinoma. ( 23714486 )
2013
37
Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. ( 24356933 )
2013
38
Gastroesophageal junction adenocarcinoma metastasizing to gingiva. ( 23776844 )
2013
39
Results of docetaxel plus oxaliplatin (DOCOX) A+ cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. ( 23747051 )
2013
40
Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. ( 23412351 )
2012
41
Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. ( 22472851 )
2012
42
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. ( 21617522 )
2012
43
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. ( 21769462 )
2012
44
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. ( 22646280 )
2012
45
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. ( 20574790 )
2011
46
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. ( 21063792 )
2011
47
Gastroesophageal junction adenocarcinoma of young patients who underwent curative surgery: a comparative analysis with older group. ( 21264755 )
2011
48
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. ( 21338186 )
2010
49
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. ( 20458043 )
2010
50
Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. ( 19139425 )
2009

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.05 ERBB2 IL1B
2 10.48 ERBB2 SNAI1

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.16 ERBB2 IL1B
2 positive regulation of epithelial to mesenchymal transition GO:0010718 8.96 IL1B SNAI1
3 regulation of ERK1 and ERK2 cascade GO:0070372 8.62 ERBB2 IL1B

Sources for Gastroesophageal Junction Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....